![Stephen Man BSc, PhD](https://profiles-cardiff.imgix.net/attachments/8610?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Overview
I retired as a Reader in the Division of Cancer and Genetics (DCG), in the School of Medicine. My research was focussed on the role of the immune system in cancer. I am an expert on human T cells and for several years, I studied the role of these cells in leukaemia. My research funded by Bloodwise and Cancer Research Wales has identified novel targets for immune attack, and shown that patients with more aggressive disease have abnormal T cell populations. Our aim was to translate these findings for patient benefit.
Outside the laboratory, I was active in community engagement (details under Engagement tab) and I was a co-founder of the Cardiff University International Staff Network. This network is a voluntary staff organisation that provides advice and support to international staff in their transition to life in Cardiff and the UK. We were recognised by a Cardiff University "Celebrating Excellence Award for Voluntary Contribution" in 2019.
Publication
2023
- Dolton, G. et al. 2023. Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. Cell 186 (16), pp.3333-3349. E27. (10.1016/j.cell.2023.06.020)
2021
- Man, S. et al. 2021. Synthetic peptides with inadvertent chemical modifications can activate potentially autoreactive T cells. The Journal of Immunology 207 (4), pp.1009-1017. (10.4049/jimmunol.2000756)
- Rastogi, N. et al. 2021. Use of an anti-CD200 blocking antibody improves immune responses to AML in vitro and in vivo. British Journal of Haematology 193 (1), pp.155-159. (10.1111/bjh.17125)
2020
- Elston, L. et al. 2020. Increased frequency of CD4+PD-1+HLA-DR+ T cells is associated with disease progression in CLL. British Journal of Haematology 188 (6), pp.872-880. (10.1111/bjh.16260)
2019
- Man, S. and Henley, P. 2019. Chronic lymphocytic leukaemia: the role of T cells in a B cell disease. British Journal of Haematology 186 (2), pp.220-233. (10.1111/bjh.15918)
2018
- Pirotte, E. F. et al. 2018. Sensitivity to inhibition of DNA repair by Olaparib in novel oropharyngeal cancer cell lines infected with Human Papillomavirus. PLoS ONE 13 (12), pp.-. e0207934. (10.1371/journal.pone.0207934)
2017
- Dockree, T. et al. 2017. CD8+ T-cell specificity is compromised at a defined MHCI/CD8 affinity threshold. Immunology and Cell Biology 95 (1), pp.68-76. (10.1038/icb.2016.85)
2016
- Parry, H. M. et al., 2016. Cytomegalovirus infection does not impact on survival or time to first treatment in patients with Chronic Lymphocytic Leukaemia. American Journal of Hematology 91 (8), pp.776-781. (10.1002/ajh.24403)
- Sacco, J. J. et al., 2016. Systemic listeriosis following vaccination with the attenuatedListeria monocytogenestherapeutic vaccine, ADXS11-001. Human Vaccines & Immunotherapeutics 12 (4), pp.1085-1086. (10.1080/21645515.2015.1121338)
2015
- Coles, S. J. et al. 2015. The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse. Leukemia 29 , pp.1952-1954. (10.1038/leu.2015.62)
- Reid, R. et al. 2015. CD8+ T-cell recognition of a synthetic epitope formed by t-butyl modification. Immunology 144 (3), pp.495-505. (10.1111/imm.12398)
2014
- Tristram, A. et al. 2014. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT³VIN): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology 15 (12), pp.1361-1368. (10.1016/S1470-2045(14)70456-5)
- Stanton, R. J. et al. 2014. HCMV pUL135 remodels the actin cytoskeleton to impair immune recognition of infected cells. Cell Host and Microbe 16 (2), pp.201-214. (10.1016/j.chom.2014.07.005)
2013
- Wong, R. F. et al. 2013. Blinatumomab induces autologous T cell killing of chronic lymphocytic leukemia cells. Haematologica 98 (12), pp.1930-1938. (10.3324/haematol.2012.082248)
- Man, S. 2013. Back to the future: learning from cancer vaccine trials in Cardiff. Applied Immunohistochemistry and Molecular Morphology 21 (2), pp.110-115. (10.1097/PAI.0b013e3182811612)
- Al-Taei, S. et al. 2013. Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy. Cancer Immunology, Immunotherapy 62 (12), pp.1821-1830. (10.1007/s00262-013-1488-5)
2012
- Nunes, C. T. et al. 2012. Expansion of a CD8+PD-1+ replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clinical Cancer Research 18 (3), pp.678-687. (10.1158/1078-0432.CCR-11-2630)
- Coles, S. et al. 2012. Expression of CD200 on AML blasts directly suppresses memory T-cell function [Letter]. Leukemia 26 (9), pp.2148-2151. (10.1038/leu.2012.77)
- Coles, S. et al. 2012. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells [Letter]. Leukemia 26 (9), pp.2146-2148. (10.1038/leu.2012.75)
2011
- Coles, S. et al. 2011. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 25 (5), pp.792-799. (10.1038/leu.2011.1)
- Chan, P. K. S. et al., 2011. T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer. Journal of Medical Virology 83 (6), pp.1023-1030. (10.1002/jmv.21889)
- Coles, S. et al. 2011. CD200 inhibits memory Th1 cell function in acute myeloid leukaemia (AML)[Abstract]. Immunology 135 (S1), pp.178. (10.1111/j.1365-2567.2011.03534.x)
- Nunes, C. T. et al. 2011. A novel tumor antigen derived from enhanced degradation of Bax protein in human cancers. Cancer Research 71 (16), pp.5435-5444. (10.1158/0008-5472.CAN-11-0393)
2010
- Campo, M. S. et al., 2010. HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology 407 (1), pp.137-142. (10.1016/j.virol.2010.07.044)
- Chan, P. K. S. et al., 2010. T-Cell response to human papillomavirus type 58 L1, E6, and E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer. Clinical and Vaccine Immunology 17 (9), pp.1315-1321. (10.1128/CVI.00105-10)
- Coles, S. et al. 2010. Over-expression of CD200 un acute myeloid leukemia mediates the expansion of regulatory T-lymphocytes and directly inhibits natural killer cell tumor immunity [Abstract]. Blood 116 (21), pp.218-218.
2008
- Tabi, Z. and Man, S. 2008. Cancer vaccines and immune monitoring (an overview). In: Hayat, M. A. ed. General methods and overviews, lung carcinoma and prostate carcinoma:. Methods of cancer diagnosis, therapy and prognosis Vol. 2.Springer. , pp.129-160. (10.1007/978-1-4020-8442-3)
- Thomas, K. J. et al., 2008. HPV16 E629-38-specific T cells kill cervical carcinoma cells despite partial evasion of T-cell effector function. International Journal of Cancer 122 (12), pp.2791-2799. (10.1002/ijc.23475)
2007
- Capper, R. et al. 2007. The nature of telomere fusion and a definition of the critical telomere length in human cells. Genes and Development 21 (19), pp.2495-2508. (10.1101/gad.439107)
2006
- McCarthy, C. , Youde, S. J. and Man, S. T. 2006. Definition of an HPV18/45 cross-reactive human T-cell epitope after DNA immunisation of HLA-A2/KB transgenic mice. International Journal of Cancer 118 (10), pp.2514-21. (10.1002/ijc.21643)
- Fiander, A. N. et al. 2006. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. International Journal of Gynecological Cancer 16 (3), pp.1075-1081. (10.1111/j.1525-1438.2006.00598.x)
2005
- Youde, S. J. et al. 2005. Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line. International Journal of Cancer 114 (4), pp.606-12. (10.1002/ijc.20779)
- Hill, S. C. et al., 2005. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. Journal of Immunology 174 (1), pp.41-50.
- Lyons, G. E. et al., 2005. T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunology, Immunotherapy 55 (9), pp.1142-1150. (10.1007/s00262-005-0103-9)
- Smith, K. L. et al., 2005. Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18. International Immunology 17 (2), pp.167-176. (10.1093/intimm/dxh197)
- Wall, S. R. et al., 2005. Cervical human papillomavirus infection and squamous intraepithelial lesions in rural Gambia, West Africa: viral sequence analysis and epidemiology. British Journal of Cancer 93 (9), pp.1068-1076. (10.1038/sj.bjc.6602736)
2004
- Man, S. T. et al. 2004. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood 103 (12), pp.4613-4615. (10.1182/blood-2003-11-3903)
- Smyth, L. J. C. et al., 2004. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clinical Cancer Research 10 (9), pp.2954-2961. (10.1158/1078-0432.CCR-03-0703)
2003
- Adams, M. et al., 2003. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R). Vaccine 21 (7-8), pp.787-90. (10.1016/S0264-410X(02)00599-6)
- Fiander, A. N. and Man, S. T. 2003. Antiviral vaccination for treating intraepithelial neoplasia. In: Maclean, A. B. , Singer, A. and Critchley, H. eds. Lower Genital Tract Neoplasia. London: RCOG Press. , pp.192-209.
2002
- Palmowski, M. J. et al., 2002. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. The Journal of Immunology 168 (9), pp.4391-4398. (10.4049/jimmunol.168.9.4391)
- Savage, P. et al., 2002. Anti-viral cytotoxic T cells inhibit the growth of cancer cells with antibody targeted hla class I/peptide complexes in scid mice. International Journal of Cancer 98 (4), pp.561-566. (10.1002/ijc.10219)
- Savage, P. et al., 2002. Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes. British Journal of Cancer 86 (8), pp.1336-1342. (10.1038/sj.bjc.6600223)
2001
- Evans, M. et al. 2001. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. The Journal of Immunology 167 (9), pp.5420-5428.
- Adams, M. et al., 2001. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 19 (17-19), pp.2549-2556. (10.1016/S0264-410X(00)00488-6)
- Adams, M. et al., 2001. Clinical studies of human papilloma vaccines in cervical cancer. In: Mackiewicz, A. , Kurpisz, M. and Zeromski, J. eds. Progress in Basic and Clinical Immunology. Advances in Experimental Medicine and Biology Vol. 442.New York: Kluwer Academic/Plenum Publishers. , pp.419-427. (10.1007/978-1-4615-0685-0_61)
- Lawson, T. et al. 2001. Functional differences between influenza A-specific cytotoxic T lymphocyte clones expressing dominant and subdominant TCR. International Immunology 13 (11), pp.1383-1390. (10.1093/intimm/13.11.1383)
- Lawson, T. et al. 2001. Influenza A antigen exposure selects dominant Vbeta17+ TCR in human CD8+ cytotoxic T cell responses. International Immunology 13 (11), pp.1373-1381. (10.1093/intimm/13.11.1373)
- Man, S. T. 2001. Recognition of human tumours: viral antigens as immunological targets for cytotoxic T cells. In: Robbins, R. A. and Rees, R. eds. Cancer Immunology. Immunology and Medicine Vol. 30.Springer. , pp.123-145.
- Man, S. T. and Fiander, A. N. 2001. Immunology of human papillomavirus infection in lower genital tract neoplasia [review]. Best Practice & Research Clinical Obstetrics & Gynaecology 15 (5), pp.701-714. (10.1053/beog.2001.0215)
2000
- Borysiewicz., L. K. and Man, S. T. 2000. Vaccinia-based human papillomavirus vaccines in cervical cancer. In: Stern, P. L. , Beverley, P. C. L. and Carroll, M. W. eds. Cancer vaccines and immunotherapy. Cambridge, UK: Cambridge University Press. , pp.62-81.
- Evans, M. , Man, S. T. and Borysiewicz, L. K. 2000. Vaccine strategies for cancer. In: Weissberg, P. ed. Horizons in Medicine. Vol. 12, London: Royal College of Physicians. , pp.289-300.
- Youde, S. J. et al. 2000. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. Cancer Research 60 (2), pp.365-371.
1999
- Man, S. T. et al. 1999. Recombinant vaccinia virus. In: Tindle, R. W. ed. Vaccines for Human Papillomavirus Infection and anogenital disease, 14th ed.. Medical Intelligence Unit Austin, Texas: R.G. Landes Company. , pp.69-90.
1997
- Nimako, M. et al., 1997. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer Research 57 (21), pp.4855-4861.
- Fiander, A. N. et al. 1997. Therapeutic vaccines for cervical cancer: concept and clinical results. Biodrugs -Auckland- 8 (5), pp.331-338. (10.2165/00063030-199708050-00001)
1996
- Borysiewicz, L. K. et al., 1996. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. The Lancet 347 (9014), pp.1523-1527. (10.1016/s0140-6736(96)90674-1)
1995
- Borysiewicz, L. K. et al., 1995. Development and initial clinical studies of TA-HPV in cervical cancer. European Journal of Cancer 31 (supp 3), pp.17-17. (10.1016/0959-8049(95)99882-z)
Articles
- Dolton, G. et al. 2023. Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. Cell 186 (16), pp.3333-3349. E27. (10.1016/j.cell.2023.06.020)
- Man, S. et al. 2021. Synthetic peptides with inadvertent chemical modifications can activate potentially autoreactive T cells. The Journal of Immunology 207 (4), pp.1009-1017. (10.4049/jimmunol.2000756)
- Rastogi, N. et al. 2021. Use of an anti-CD200 blocking antibody improves immune responses to AML in vitro and in vivo. British Journal of Haematology 193 (1), pp.155-159. (10.1111/bjh.17125)
- Elston, L. et al. 2020. Increased frequency of CD4+PD-1+HLA-DR+ T cells is associated with disease progression in CLL. British Journal of Haematology 188 (6), pp.872-880. (10.1111/bjh.16260)
- Man, S. and Henley, P. 2019. Chronic lymphocytic leukaemia: the role of T cells in a B cell disease. British Journal of Haematology 186 (2), pp.220-233. (10.1111/bjh.15918)
- Pirotte, E. F. et al. 2018. Sensitivity to inhibition of DNA repair by Olaparib in novel oropharyngeal cancer cell lines infected with Human Papillomavirus. PLoS ONE 13 (12), pp.-. e0207934. (10.1371/journal.pone.0207934)
- Dockree, T. et al. 2017. CD8+ T-cell specificity is compromised at a defined MHCI/CD8 affinity threshold. Immunology and Cell Biology 95 (1), pp.68-76. (10.1038/icb.2016.85)
- Parry, H. M. et al., 2016. Cytomegalovirus infection does not impact on survival or time to first treatment in patients with Chronic Lymphocytic Leukaemia. American Journal of Hematology 91 (8), pp.776-781. (10.1002/ajh.24403)
- Sacco, J. J. et al., 2016. Systemic listeriosis following vaccination with the attenuatedListeria monocytogenestherapeutic vaccine, ADXS11-001. Human Vaccines & Immunotherapeutics 12 (4), pp.1085-1086. (10.1080/21645515.2015.1121338)
- Coles, S. J. et al. 2015. The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse. Leukemia 29 , pp.1952-1954. (10.1038/leu.2015.62)
- Reid, R. et al. 2015. CD8+ T-cell recognition of a synthetic epitope formed by t-butyl modification. Immunology 144 (3), pp.495-505. (10.1111/imm.12398)
- Tristram, A. et al. 2014. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT³VIN): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology 15 (12), pp.1361-1368. (10.1016/S1470-2045(14)70456-5)
- Stanton, R. J. et al. 2014. HCMV pUL135 remodels the actin cytoskeleton to impair immune recognition of infected cells. Cell Host and Microbe 16 (2), pp.201-214. (10.1016/j.chom.2014.07.005)
- Wong, R. F. et al. 2013. Blinatumomab induces autologous T cell killing of chronic lymphocytic leukemia cells. Haematologica 98 (12), pp.1930-1938. (10.3324/haematol.2012.082248)
- Man, S. 2013. Back to the future: learning from cancer vaccine trials in Cardiff. Applied Immunohistochemistry and Molecular Morphology 21 (2), pp.110-115. (10.1097/PAI.0b013e3182811612)
- Al-Taei, S. et al. 2013. Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy. Cancer Immunology, Immunotherapy 62 (12), pp.1821-1830. (10.1007/s00262-013-1488-5)
- Nunes, C. T. et al. 2012. Expansion of a CD8+PD-1+ replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clinical Cancer Research 18 (3), pp.678-687. (10.1158/1078-0432.CCR-11-2630)
- Coles, S. et al. 2012. Expression of CD200 on AML blasts directly suppresses memory T-cell function [Letter]. Leukemia 26 (9), pp.2148-2151. (10.1038/leu.2012.77)
- Coles, S. et al. 2012. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells [Letter]. Leukemia 26 (9), pp.2146-2148. (10.1038/leu.2012.75)
- Coles, S. et al. 2011. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 25 (5), pp.792-799. (10.1038/leu.2011.1)
- Chan, P. K. S. et al., 2011. T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer. Journal of Medical Virology 83 (6), pp.1023-1030. (10.1002/jmv.21889)
- Coles, S. et al. 2011. CD200 inhibits memory Th1 cell function in acute myeloid leukaemia (AML)[Abstract]. Immunology 135 (S1), pp.178. (10.1111/j.1365-2567.2011.03534.x)
- Nunes, C. T. et al. 2011. A novel tumor antigen derived from enhanced degradation of Bax protein in human cancers. Cancer Research 71 (16), pp.5435-5444. (10.1158/0008-5472.CAN-11-0393)
- Campo, M. S. et al., 2010. HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology 407 (1), pp.137-142. (10.1016/j.virol.2010.07.044)
- Chan, P. K. S. et al., 2010. T-Cell response to human papillomavirus type 58 L1, E6, and E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer. Clinical and Vaccine Immunology 17 (9), pp.1315-1321. (10.1128/CVI.00105-10)
- Coles, S. et al. 2010. Over-expression of CD200 un acute myeloid leukemia mediates the expansion of regulatory T-lymphocytes and directly inhibits natural killer cell tumor immunity [Abstract]. Blood 116 (21), pp.218-218.
- Thomas, K. J. et al., 2008. HPV16 E629-38-specific T cells kill cervical carcinoma cells despite partial evasion of T-cell effector function. International Journal of Cancer 122 (12), pp.2791-2799. (10.1002/ijc.23475)
- Capper, R. et al. 2007. The nature of telomere fusion and a definition of the critical telomere length in human cells. Genes and Development 21 (19), pp.2495-2508. (10.1101/gad.439107)
- McCarthy, C. , Youde, S. J. and Man, S. T. 2006. Definition of an HPV18/45 cross-reactive human T-cell epitope after DNA immunisation of HLA-A2/KB transgenic mice. International Journal of Cancer 118 (10), pp.2514-21. (10.1002/ijc.21643)
- Fiander, A. N. et al. 2006. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. International Journal of Gynecological Cancer 16 (3), pp.1075-1081. (10.1111/j.1525-1438.2006.00598.x)
- Youde, S. J. et al. 2005. Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line. International Journal of Cancer 114 (4), pp.606-12. (10.1002/ijc.20779)
- Hill, S. C. et al., 2005. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. Journal of Immunology 174 (1), pp.41-50.
- Lyons, G. E. et al., 2005. T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunology, Immunotherapy 55 (9), pp.1142-1150. (10.1007/s00262-005-0103-9)
- Smith, K. L. et al., 2005. Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18. International Immunology 17 (2), pp.167-176. (10.1093/intimm/dxh197)
- Wall, S. R. et al., 2005. Cervical human papillomavirus infection and squamous intraepithelial lesions in rural Gambia, West Africa: viral sequence analysis and epidemiology. British Journal of Cancer 93 (9), pp.1068-1076. (10.1038/sj.bjc.6602736)
- Man, S. T. et al. 2004. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood 103 (12), pp.4613-4615. (10.1182/blood-2003-11-3903)
- Smyth, L. J. C. et al., 2004. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clinical Cancer Research 10 (9), pp.2954-2961. (10.1158/1078-0432.CCR-03-0703)
- Adams, M. et al., 2003. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R). Vaccine 21 (7-8), pp.787-90. (10.1016/S0264-410X(02)00599-6)
- Palmowski, M. J. et al., 2002. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. The Journal of Immunology 168 (9), pp.4391-4398. (10.4049/jimmunol.168.9.4391)
- Savage, P. et al., 2002. Anti-viral cytotoxic T cells inhibit the growth of cancer cells with antibody targeted hla class I/peptide complexes in scid mice. International Journal of Cancer 98 (4), pp.561-566. (10.1002/ijc.10219)
- Savage, P. et al., 2002. Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes. British Journal of Cancer 86 (8), pp.1336-1342. (10.1038/sj.bjc.6600223)
- Evans, M. et al. 2001. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. The Journal of Immunology 167 (9), pp.5420-5428.
- Adams, M. et al., 2001. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 19 (17-19), pp.2549-2556. (10.1016/S0264-410X(00)00488-6)
- Lawson, T. et al. 2001. Functional differences between influenza A-specific cytotoxic T lymphocyte clones expressing dominant and subdominant TCR. International Immunology 13 (11), pp.1383-1390. (10.1093/intimm/13.11.1383)
- Lawson, T. et al. 2001. Influenza A antigen exposure selects dominant Vbeta17+ TCR in human CD8+ cytotoxic T cell responses. International Immunology 13 (11), pp.1373-1381. (10.1093/intimm/13.11.1373)
- Man, S. T. and Fiander, A. N. 2001. Immunology of human papillomavirus infection in lower genital tract neoplasia [review]. Best Practice & Research Clinical Obstetrics & Gynaecology 15 (5), pp.701-714. (10.1053/beog.2001.0215)
- Youde, S. J. et al. 2000. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. Cancer Research 60 (2), pp.365-371.
- Nimako, M. et al., 1997. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. Cancer Research 57 (21), pp.4855-4861.
- Fiander, A. N. et al. 1997. Therapeutic vaccines for cervical cancer: concept and clinical results. Biodrugs -Auckland- 8 (5), pp.331-338. (10.2165/00063030-199708050-00001)
- Borysiewicz, L. K. et al., 1996. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. The Lancet 347 (9014), pp.1523-1527. (10.1016/s0140-6736(96)90674-1)
- Borysiewicz, L. K. et al., 1995. Development and initial clinical studies of TA-HPV in cervical cancer. European Journal of Cancer 31 (supp 3), pp.17-17. (10.1016/0959-8049(95)99882-z)
Book sections
- Tabi, Z. and Man, S. 2008. Cancer vaccines and immune monitoring (an overview). In: Hayat, M. A. ed. General methods and overviews, lung carcinoma and prostate carcinoma:. Methods of cancer diagnosis, therapy and prognosis Vol. 2.Springer. , pp.129-160. (10.1007/978-1-4020-8442-3)
- Fiander, A. N. and Man, S. T. 2003. Antiviral vaccination for treating intraepithelial neoplasia. In: Maclean, A. B. , Singer, A. and Critchley, H. eds. Lower Genital Tract Neoplasia. London: RCOG Press. , pp.192-209.
- Adams, M. et al., 2001. Clinical studies of human papilloma vaccines in cervical cancer. In: Mackiewicz, A. , Kurpisz, M. and Zeromski, J. eds. Progress in Basic and Clinical Immunology. Advances in Experimental Medicine and Biology Vol. 442.New York: Kluwer Academic/Plenum Publishers. , pp.419-427. (10.1007/978-1-4615-0685-0_61)
- Man, S. T. 2001. Recognition of human tumours: viral antigens as immunological targets for cytotoxic T cells. In: Robbins, R. A. and Rees, R. eds. Cancer Immunology. Immunology and Medicine Vol. 30.Springer. , pp.123-145.
- Borysiewicz., L. K. and Man, S. T. 2000. Vaccinia-based human papillomavirus vaccines in cervical cancer. In: Stern, P. L. , Beverley, P. C. L. and Carroll, M. W. eds. Cancer vaccines and immunotherapy. Cambridge, UK: Cambridge University Press. , pp.62-81.
- Evans, M. , Man, S. T. and Borysiewicz, L. K. 2000. Vaccine strategies for cancer. In: Weissberg, P. ed. Horizons in Medicine. Vol. 12, London: Royal College of Physicians. , pp.289-300.
- Man, S. T. et al. 1999. Recombinant vaccinia virus. In: Tindle, R. W. ed. Vaccines for Human Papillomavirus Infection and anogenital disease, 14th ed.. Medical Intelligence Unit Austin, Texas: R.G. Landes Company. , pp.69-90.
Research
My research was focussed on the role of the immune system in cancer, in particular trying to develop new ways to treat cancer or to monitor the status of the immune system to identify poor prognosis patients. My laboratory developed methods to detect, isolate and grow cancer specific T cells and used these to study patient samples (chronic lymphocytic leukaemia).
Teaching
I was the teaching lead for the Division of Cancer and Genetics, liaising with C4ME and providing support for teaching activities related to UG medical student teaching. I used to lecture and perform course assessment for the Advanced Immunology (ME3045) and Immunopathology and Immunotherapy (ME3046) Modules.
I was a personal tutor to 35 medical students (years 1-5) and supervised numerous literature and laboratory SSC projects. I supervised 27 medical students on community engagement projects (Interactive Health Workshops for Welsh Primary Schools).
I interviewed candidate medical school students (MMIs).
Biography
Career Overview
- 2012-2024: Reader, Division of Cancer and Genetics, School of Medicine, Cardiff University
- 2002-2012: Senior Lecturer, Infection and Immunity, School of Medicine, Cardiff University
- 1995-2003: Royal Society University Research Fellow, Department of Medicine, University of Wales College of Medicine
- 1994-1995: Post-doctoral Research Fellow, Department of Medicine, University of Wales College of Medicine
- 1990-1994: Post-doctoral Research Fellow, Department of Microbiology, University of Virginia, USA
Professional memberships
- Member of the British Society for Immunology
Supervisions
I am interested in supervising PhD students in the following areas:
- Cancer Immunology, in particular prostate cancer
- Immunotherapy
- Novel tumour antigens
- Therapeutic cancer vaccines
- Overcoming cancer associated immunosuppression
- T cells as biomarkers for disease progression and/or response to treatment
Engagement
I have been active in several aspects of public engagement:
-
Interactive Health Workshops. These have been run by medical students as part of their 3rd or 4th year SSC projects. The students visit Welsh primary schools to teach children (aged 9-11) about the human body and healthy living. The workshops are composed of "hands-on" activities, demonstrations and quizzes designed to keep the attention of the children and ot make learning fun. The project in it's current form was started by funding from the Cardiff University CIty Region Exchange project. So far, 49 schools have been visited in Cardiff, Caerphilly, Methyr Tydfill and Pontypridd.
-
Science in Health. I have hosted work-experience students (Yr 12) in my laboratory.
-
Increasing public understanding of science, particularly cancer immunology. I have given talks to charity fundraisers and patient support groups.
Contact Details
Research themes
Specialisms
- T cell immunity
- Tumour immunology